

Ref. No: 1602
Date: 12/03/25
Subject: HAE and IG

REQUEST

Q1. In the past 3 months, how many patients have received the following treatments (for any disease):

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Firazyr (Icatibant)
- Icatibant - any brand except Firazyr
- Orladeyo (Berotralstat)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Takhzyro (Lanadelumab)
- Garadacimab (Andembry)

Q2. In the past 3 months how many patients have received the following immunoglobulin treatments (for any disease):

- Cutaquig
- Cuvitru
- Gammagard
- Gammanorm
- Hizentra
- Hyqvia
- Intratect
- Iqymune
- Kiovig
- Privigen
- Octagam
- Panzyga
- Subgam
- Any other normal immunoglobulin

RESPONSE

STHK legacy response:

Q1. In the past 3 months, how many patients have received the following treatments (for any disease):

- Berinert (Human C1-esterase inhibitor) - 0
- Cinryze (Human C1-esterase inhibitor) - 0
- Firazyr (Icatibant) - 0
- Icatibant - any brand except Firazyr - 0
- Orladeyo (Berotralstat) - 0
- Ruconest (Recombinant human C1-esterase inhibitor) - 0
- Takhzyro (Lanadelumab) - 0
- Garadacimab (Andembry) - 0

Q2. In the past 3 months how many patients have received the following immunoglobulin treatments (for any disease):

- Cutaquig - 0
- Cuvitru - 0
- Gammagard - 0
- Gammanorm - 0
- Hizentra - <5
- Hyqvia - 0
- Intratect - 10
- Iqymune - 0
- Kiovig - 0
- Privigen - 0
- Octagam - 15
- Panzyga - 0
- Subgam - 0
- Any other normal immunoglobulin - 0